Epitope Diagnostics

Executive Summary

Epitope Diagnostics Inc. (EDI) is a San Diego-based private medical device manufacturer with over three decades of experience in the in-vitro diagnostics (IVD) market. The company specializes in niche immunoassays, offering a diversified portfolio of chemiluminescence (CLIA) kits, ELISA kits, lateral flow rapid tests, and specialized antibodies for clinical diagnostics and research. EDI is ISO 13485:2016 certified and US FDA registered, underscoring its commitment to quality and regulatory compliance. With products spanning infectious disease, autoimmune, and metabolic panels, the company serves a global customer base of hospitals, reference labs, and research institutions. Despite its long-standing presence, EDI remains a small player in a competitive landscape, relying on differentiated, high-specificity assays and cost-effective manufacturing to maintain its niche.

Upcoming Catalysts (preview)

• Q4 2025FDA 510(k) clearance for a novel CLIA autoimmune panel70% success
• Q1 2026Launch of a rapid lateral flow test for an emerging respiratory virus60% success
• Q2 2026Strategic distribution partnership for entry into the Asian IVD market50% success